| Code | CSB-RA858415MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to resugobart, targeting sclerostin (SOST), a glycoprotein secreted primarily by osteocytes that functions as a negative regulator of bone formation. SOST inhibits the Wnt signaling pathway by binding to LRP5/6 co-receptors, thereby suppressing osteoblast differentiation and activity. Dysregulation of SOST expression is implicated in various skeletal disorders, including osteoporosis, where elevated sclerostin levels contribute to decreased bone mineral density and increased fracture risk. Loss-of-function mutations in the SOST gene cause sclerosteosis and van Buchem disease, rare conditions characterized by excessive bone formation.
Resugobart represents a therapeutic antibody designed to neutralize sclerostin, promoting bone formation through disinhibition of the Wnt pathway. This biosimilar provides researchers with a valuable tool for investigating sclerostin biology, bone metabolism mechanisms, and skeletal disease pathophysiology. It supports studies examining osteoblast function, bone remodeling processes, and potential therapeutic strategies for metabolic bone disorders. The antibody enables exploration of SOST-mediated signaling in both physiological and pathological contexts.
There are currently no reviews for this product.